(NYSE: ANVS) Annovis Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.64%.
Annovis Bio's earnings in 2026 is -$40,923,510.On average, 4 Wall Street analysts forecast ANVS's earnings for 2026 to be -$65,732,038, with the lowest ANVS earnings forecast at -$65,191,547, and the highest ANVS earnings forecast at -$65,482,581. On average, 4 Wall Street analysts forecast ANVS's earnings for 2027 to be -$54,953,397, with the lowest ANVS earnings forecast at -$66,210,165, and the highest ANVS earnings forecast at -$42,199,885.
In 2028, ANVS is forecast to generate -$66,615,533 in earnings, with the lowest earnings forecast at -$67,907,861 and the highest earnings forecast at -$64,391,204.